Geode Capital Management’s Kalaris Therapeutics, Inc. Common Stock KLRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $68K | Sell |
25,476
-1,311
| -5% | -$3.5K | ﹤0.01% | 4155 |
|
|
2025
Q1 | $215K | Buy |
26,787
+1,362
| +5% | +$10.9K | ﹤0.01% | 3826 |
|
|
2024
Q4 | $246K | Sell |
25,425
-34
| -0.1% | -$329 | ﹤0.01% | 3837 |
|
|
2024
Q3 | $474K | Sell |
25,459
-2,692
| -10% | -$50.1K | ﹤0.01% | 3595 |
|
|
2024
Q2 | $468K | Sell |
28,151
-27,237
| -49% | -$453K | ﹤0.01% | 3582 |
|
|
2024
Q1 | $962K | Buy |
55,388
+899
| +2% | +$15.6K | ﹤0.01% | 3372 |
|
|
2023
Q4 | $852K | Buy |
54,489
+3,218
| +6% | +$50.3K | ﹤0.01% | 3412 |
|
|
2023
Q3 | $2.54M | Buy |
51,271
+11,123
| +28% | +$550K | ﹤0.01% | 2987 |
|
|
2023
Q2 | $3.14M | Buy |
40,148
+5,771
| +17% | +$451K | ﹤0.01% | 2944 |
|
|
2023
Q1 | $3.12M | Buy |
34,377
+1,246
| +4% | +$113K | ﹤0.01% | 2839 |
|
|
2022
Q4 | $3.91M | Buy |
33,131
+315
| +1% | +$37.2K | ﹤0.01% | 2782 |
|
|
2022
Q3 | $5.96M | Buy |
32,816
+8,857
| +37% | +$1.61M | ﹤0.01% | 2576 |
|
|
2022
Q2 | $2.15M | Buy |
23,959
+45
| +0.2% | +$4.04K | ﹤0.01% | 3087 |
|
|
2022
Q1 | $3.71M | Buy |
23,914
+516
| +2% | +$80.1K | ﹤0.01% | 2958 |
|
|
2021
Q4 | $6.96M | Buy |
23,398
+1,043
| +5% | +$310K | ﹤0.01% | 2694 |
|
|
2021
Q3 | $12.9M | Buy |
22,355
+3,591
| +19% | +$2.07M | ﹤0.01% | 2278 |
|
|
2021
Q2 | $8.52M | Buy |
18,764
+173
| +0.9% | +$78.5K | ﹤0.01% | 2573 |
|
|
2021
Q1 | $10M | Buy |
18,591
+5,118
| +38% | +$2.75M | ﹤0.01% | 2370 |
|
|
2020
Q4 | $11.9M | Buy |
13,473
+476
| +4% | +$421K | ﹤0.01% | 2045 |
|
|
2020
Q3 | $8.22M | Buy |
+12,997
| New | +$8.22M | ﹤0.01% | 2072 |
|